Clinical Trial Update: Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating low-dose interleukin-2 plus interferon-alpha as adjuvant immunotherapy for renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Interferon Alfa (interferon alfa)
• Proleukin (aldesleukin)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: COMPLETED